Web-Based Exercise for Neuropathy and Quality of Life in Breast Cancer

Launched by BILECIK SEYH EDEBALI UNIVERSITESI · Mar 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a web-based exercise program designed to help breast cancer patients manage a side effect called chemotherapy-induced peripheral neuropathy (CIPN). CIPN can cause pain, tingling, and weakness in the hands and feet due to nerve damage from chemotherapy drugs, particularly those used to treat breast cancer. The goal of the study is to see if regular exercise, guided by a physiotherapist through an online platform, can improve these symptoms and enhance the overall quality of life for patients undergoing treatment.

To participate, women aged 18 to 75 who are currently receiving taxane-based chemotherapy for stage II-III breast cancer and experiencing at least one neuropathy symptom may be eligible. Participants will engage in the web-based exercise program for eight weeks and will provide feedback on their symptoms and quality of life before and after the program. It’s important to note that participants need internet access and must not have certain health conditions that could interfere with the study. This trial is not yet recruiting, but it aims to provide valuable insights into how exercise can help cancer patients cope with challenging side effects.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Able to understand and speak Turkish,
• • Over 18 years of age,
• • Receiving taxane-based chemotherapy in daytime chemotherapy units,
• • Reporting at least one neuropathy symptom according to CIPNAT,
• • Diagnosed with stage II-III breast cancer,
• • Receiving a planned weekly taxane-based chemotherapy infusion dose (70-99 mg/m², 100-129 mg/m², 130-159 mg/m², 160 mg/m² and above) and completing 8 treatment cycles,
• • Having internet access,
• • No history of deep vein thrombosis,
• • Not using anticoagulant medication,
• • Willing to participate in the study.
• Exclusion Criteria:
• • Younger than 18 years or older than 75 years,
• • Having central nervous system disorders affecting movement, balance, sensation, or coordination,
• • Presence of any skin infection, scar tissue, inflammation, or incision on the hands or ankles,
• • Diagnosed with a proven cardiac condition or using medication for cardiac issues,
• • Pregnant women or those in the postpartum period,
• • History of polyneuropathy before chemotherapy,
• • Cognitive impairment,
• • Presence of metal implants in the exposure area,
• • History of any other malignancy,
• • Undergoing mastectomy.
• • Withdrawal Criteria
• * Patients meeting the following conditions will be withdrawn from the study:
• • Patients whose taxane treatment protocol is changed,
• • Patients who wish to withdraw from the study,
• • Patients with a pulse rate above 100 bpm,
• • Patients receiving fewer than four weekly chemotherapy applications,
• • Women without internet access or those who do not visit the website at least five times for four hours throughout the follow-up period.